Skip to main content

Table 3 Baseline characteristics and association with survival outcomes

From: Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis

Characteristics

N

%

Median PFS (months)

HR (95% CI), p value

Median OS (months)

HR (95% CI), p value

Overall cohort

40

100

15.6

 

44.6

 

Sex

      

• Male

24

60.0

14.3

0.473 (0.205–1.092)

43.7

0.591 (0.267–1.308)

• Female

16

40.0

45.3

p = 0.080

51.3

p = 0.194

Age

      

• < 60

20

50.0%

15.4

0.691 (0.317–1.509)

43.1

0.569 (0.264–1.223)

• > 60

20

50.0%

16.0

p = 0.354

63.1

p = 0.149

T stage

      

• T3

16

40.0%

14.4

0.975 (0.413–2.299)

51.3

1.363 (0.581–3.194)

• T4

18

45.0%

25.5

p = 0.954

44.6

p = 0.477

N stage

      

• N1

16

40.0%

13.3

1.108 (0.564–2.175)

43.7

0.978 (0.516–1.852)

• N2

17

42.5%

16.0

p = 0.767

61.7

p = 0.945

Serum CEA level at diagnosis

      

• Normal

19

47.5%

48.7

2.879 (1.269–6.534)

74.2

2.355 (1.081–5.133)

• Raised

21

52.5%

12.1

p = 0.011

41.4

p = 0.031

Metastatic sites

      

• Single

22

55.0%

16.1

1.090 (0.504–2.361)

44.2

0.869 (0.406–1.859)

• Multiple

18

45.0%

14.4

p = 0.826

51.4

p = 0.717

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us